How much does tucatinib cost per month?

Tucatinib (Tucatinib) is a targeted drug used to treat HER2-positive breast cancer. It inhibits the growth and spread of cancer cells by binding to the HER2 receptor. Since being approved by the U.S. Food and Drug Administration (FDA) in December 2019, tucatinib has shown significant efficacy in the treatment of advanced or metastatic HER2-positive breast cancer.

In the United States, tucatinib has a higher price, due in large part to its development costs and clinical trial expenses. Based on 2020 data, tucatinib retails for approximately $18,500 per month. This cost includes tucatinib itself and other drugs that are often given in combination with it, such as trastuzumab (Herceptin) and capecitabine (Capecitabine).

The high price of tucatinib has sparked widespread discussions about drug accessibility and affordability. Although insurance may partially cover the costs, many patients still have to pay significant out-of-pocket costs. To alleviate this problem, Seagen and some charities offer patient assistance programs designed to help eligible patients obtain financial assistance and reduce medication costs.

In the Chinese market, as of now, tucatinib (tucatinib) has not been officially launched and its price has not yet been determined. Therefore, patients cannot purchase it domestically and need to purchase tucatinib (tucatinib) through overseas channels. There are original drugs and generic drugs abroad. Original drugs include European versions of original drugs, which cost tens of thousands of yuan and are very expensive. Foreign generic drugs include generic drugs from Laos and Bangladesh, which cost around three to four thousand yuan and have basically the same ingredients as the original drugs.

In summary, the monthly cost of tucatinib is approximately $18,500 per month in the United States, but actual costs vary by country and specific circumstances. Despite its high price, TucatinibAs an effective HER2 positive breast cancer treatment, it still provides an important treatment option for many patients. With marketing approvals and price negotiations in more countries and regions, Tucatinib is expected to benefit more patients at a more reasonable price.